Market Place
Sourcing Support
Q32 Bio to Participate in Guggenheim`s Inaugural Health Conference
05 Nov 2024 //
PR NEWSWIRE
Q32 Bio To Present ADX-097 Phase 1 Results At ASN Kidney Week
14 Oct 2024 //
PR NEWSWIRE
Q32 Bio Completes Enrollment In Phase 2 Bempikibart Dermatitis Trial
09 Jul 2024 //
PR NEWSWIRE
Q32 Bio Joins Russell 3000® Index Logo
01 Jul 2024 //
PR NEWSWIRE
Q32 Bio Q1 2024 Financials, Corporate Update
09 May 2024 //
PR NEWSWIRE
Q32 Bio Announces Closing of Merger with Homology & Placement of $42M
25 Mar 2024 //
PR NEWSWIRE
Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy
21 Feb 2024 //
PR NEWSWIRE
Q32 Bio Regains Worldwide Rights to Bempikibart (ADX-914) from Amgen
16 Nov 2023 //
PR NEWSWIRE
Q32 Bio Appoints Saul Fink, Ph.D. as Chief Technology Officer
24 Oct 2023 //
PR NEWSWIRE
Q32 and Horizon Announce Dosing of First Patient in Phase 2 Trial of Bempikibart
13 Sep 2023 //
BUSINESSWIRE
Q32 Bio and Horizon Announce Dosing of First Patient in Phase 2 Trial of ADX-914
27 Oct 2022 //
PRESS RELEASE
Q32 Bio Announces CEO Transition
20 Sep 2022 //
PRNEWSWIRE
Q32 Bio and Horizon Therapeutics Announce Collaboration in Autoimmune Diseases
15 Aug 2022 //
PRNEWSWIRE
Q32 Bio Presents New Preclinical Data at ISNF for ADX-097
23 Jun 2022 //
PRNEWSWIRE
Q32 Bio Initiates First-in-Human PI Study of ADX-097
26 May 2022 //
PRNEWSWIRE
Q32 Bio to Present Preclinical Data on Next Generation Complement ADX-097
18 Oct 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.